NCT02707263

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill medical patients as compared with guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used to demonstrate that Intravenous administration is more effective.

Conditions

• Venous Thromboembolism

Interventions

Type	Name	Description
DRUG	intravenous continuous infusion of heparin (IV UFH)
DRUG	Subcutaneous Heparin

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-04-01
• Completion: 2017-04-01
• First posted: 2016-03-14
• Last updated: 2017-04-27

Locations

1 site across 1 country: United States